The Cell And Gene Therapy Supply Chain/Logistics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Cell And Gene Therapy Supply Chain/Logistics Market:
According to The Business Research Company’s Cell And Gene Therapy Supply Chain/Logistics Global Market Report 2024, The cell and gene therapy supply chain/logistics market size has grown rapidly in recent years. It will grow from $1.25 billion in 2023 to $1.4 billion in 2024 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to growth in prevalence of chronic diseases, efficient use of supply chain requirements, rise in maintainence the drug integrity, evolved regulatory frameworks, increased emphasis on risk mitigation and compliance.
The cell and gene therapy supply chain/logistics market size is expected to see rapid growth in the next few years. It will grow to $2.15 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to expansion of personalized medicine, development of cell-free therapies, growing prevalence of chronic diseases, growing global cell therapy manufacturing market, efficient use of supply chain requirements. Major trends in the forecast period include increased research and development expenditure, adoption of advanced technologies, favorable initiatives and programs for easier access, partnerships and collaborations between cell and gene therapy companies, supply chain providers, and logistics companies, providing of customizable services to support any point of patient identification.
The increasing need for cell and gene therapies is driving the cell and gene therapy supply chain/logistics market. Cell and gene therapies are advanced medical treatments that modify cells or genes to treat diseases, offering potential breakthroughs for untreatable conditions. These cell and gene therapies need to be stored at the proper temperature and storage conditions, which can be achieved using supply chain and logistics services, which help from sourcing to distributing and storing these cell and gene therapies. For instance, in February 2022, according to Cell & Gene, a US-based online resource for research scholars, the private investment in cell and gene therapy in 2021 was $68 billion. Moreover, the number of approved cell and gene therapies experienced a 10% growth in 2021. Therefore, the increasing need for cell and gene therapies drives the cell and gene therapy supply chain/logistics market forward.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12631&type=smp
The cell and gene therapy supply chain/logistics market covered in this report is segmented –
1) By Type Of Software Solution: Cell Orchestration Platform, Enterprise Manufacturing System, Inventory Management System, Laboratory Information Management System, Logistics Management System, Patient Management System, Quality Management System, Tracking And Tracing System
2) By Mode Of Deployment: Cloud-Based Solution, On-Premises Solution
3) By Component: Cryogenic Shippers, Cryogenic Storage Freezers, Ultra-Low Freezers, Cold Chain Management Systems, Shipment, Storage Medium, Cryogenic Packout Kits, Other Components
4) By Application Area: Donor Eligibility Assessment, Sample Collection, Manufacturing, Logistics, Patient Verification, Treatment Follow-Up
5) By End User: Biobank, Cell Therapy Lab, Hospital, Research Institute, Commercial Organization
Modern technology platforms are a key trend gaining popularity in the cell and gene therapy supply chain/logistics markets. Major companies operating in the market are developing modern technology platforms for cell and gene therapies to sustain their position in the market. For instance, in April 2023, AmerisourceBergen Corporation., a US-based healthcare company specializing in cell and gene therapy supply chain logistics, launched the Cell and Gene Therapy (CGT) Integration Hub. The Cell and Gene Therapy (CGT) Integration Hub is powered by AmerisourceBergen’s innovative customer relationship management (CRM) system. It can be integrated into the biopharma platform to facilitate better monitoring of the development and delivery of cell and gene therapies.
The cell and gene therapy supply chain/logistics market report table of contents includes:
- Executive Summary
- Cell And Gene Therapy Supply Chain/Logistics Market Characteristics
- Cell And Gene Therapy Supply Chain/Logistics Market Trends And Strategies
- Cell And Gene Therapy Supply Chain/Logistics Market – Macro Economic Scenario
- Global Cell And Gene Therapy Supply Chain/Logistics Market Size and Growth
.
.
.
- Global Cell And Gene Therapy Supply Chain/Logistics Market Competitive Benchmarking
- Global Cell And Gene Therapy Supply Chain/Logistics Market Competitive Dashboard
- Key Mergers And Acquisitions In The Cell And Gene Therapy Supply Chain/Logistics Market
- Cell And Gene Therapy Supply Chain/Logistics Market Future Outlook and Potential Analysis
- Appendix
Top Major Players:
- United Parcel Service
- Thermo Fisher Scientific Inc.
- Avantor Sciences
- Lonza Group AG
- Arvato Group
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model